PT  - JOURNAL ARTICLE
AU  - JAN-MICHAEL WERNER
AU  - SASKIA KUHL
AU  - PANTELIS STAVRINOU
AU  - GABRIELE RÖHN
AU  - BORIS KRISCHEK
AU  - TOBIAS BLAU
AU  - ROLAND GOLDBRUNNER
AU  - MARCO TIMMER
TI  - Expression of FAS-L Differs from Primary to Relapsed Low-grade Gliomas and Predicts Progression-free Survival
DP  - 2017 Dec 01
TA  - Anticancer Research
PG  - 6639--6648
VI  - 37
IP  - 12
4099  - http://ar.iiarjournals.org/content/37/12/6639.short
4100  - http://ar.iiarjournals.org/content/37/12/6639.full
SO  - Anticancer Res2017 Dec 01; 37
AB  - Background/Aim: The tumor necrosis factor FAS is overexpressed in high-grade gliomas (HGG). Only little is known about FAS or FAS ligand (FAS-L) in low-grade gliomas (LGG). We explored FAS/FAS-L expression in LGG, focusing on differences in primary and relapsed LGG and on its prognostic value. Patients and Methods: A total of 133 glioma samples (73 LGG, 60 HGG) were collected. The LGG samples included 15 matched pairs of primary and relapsed tumors. RT-PCR was performed to measure FAS/FAS-L expression, using subunit A, flavoprotein variant (SDHA) as housekeeper. Clinical data included progression free- (PFS) and overall survival (OS). Results: LGG showed significantly lower FAS but higher FAS-L expression than HGG. The FAS-L expression was higher in primary compared to relapsed LGG and had a positive prognostic value concerning PFS (median 45.20 vs. 31.37 months). Conclusion: FAS-L could act as a prognostic marker and potential target in primary LGG.